FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387356970> ?p ?o ?g. }

• W4387356970 endingPage "10" @default.
• W4387356970 startingPage "1" @default.
• W4387356970 abstract "<b><i>Background:</i></b> Vascular anomalies (VAs) are increasingly being treated with PI3K/AKT/mTOR pathway inhibitors. These drugs have immunosuppressive properties and thus theoretically overexpose patients to opportunistic infections, especially <i>Pneumocystis jirovecii</i> pneumonia (PJP). PJP prophylaxis use lacks consensus. We aimed to investigate the prevalence of PJP in patients receiving mTOR/PI3K/AKT inhibitors for VAs and determine any indication for pneumocystis prophylaxis in this population. <b><i>Methods:</i></b> The study was conducted in 2 parts: (1) we sent a survey to a panel of international experts of VAs asking about their use of pneumocystis prophylaxis drugs and (2) we performed a systematic review of the literature of all published cases of patients receiving these drugs for VA to estimate the prevalence of PJP in this population. <b><i>Results:</i></b> Answers from 68 experts were analyzed: 21 (30.9%) answered they always add PJP prophylaxis when prescribing mTOR inhibitors, 20 (29.4%) case-by-case, and 27 (39.7%) never. For the systematic review, among 3,053 reports screened, 217 were included involving 1,189 patients (1,143 received sirolimus, 38 everolimus, 4 alpelisib, 4 miransertib). Among the 1,189 cases, 2 (0.2%) PJP were reported: one under sirolimus and one under everolimus. Thus, the prevalence of PJP was estimated at 0.88 cases/1,000 patients under sirolimus (95% CI: −0.84 to 2.59) and 26.31 cases/1,000 under everolimus (95% CI: −24.58 to 77.18). Patients with PJP never received prophylaxis drugs. We found no PJP cases under alpelisib and miransertib. PJP prophylaxis was given in 218 (18.3%) cases, more frequently for children (91.3 vs. 77.2% in the non-prophylaxis group, <i>p</i> = 0.012), mostly trimethoprim-sulfamethoxazole (186 patients, 85.3%). <b><i>Conclusion:</i></b> Our study shows that even if PJP is a rare event, it may occur in patients with VAs treated with an mTOR inhibitor. Although our results cannot allow for revising guidelines, prophylaxis with TMP-SMX might be appropriate for a subgroup of patients with risk factors for PJP." @default.
• W4387356970 created "2023-10-06" @default.
• W4387356970 creator A5001564881 @default.
• W4387356970 creator A5042930843 @default.
• W4387356970 creator A5051498016 @default.
• W4387356970 creator A5056285508 @default.
• W4387356970 creator A5064459488 @default.
• W4387356970 creator A5065871425 @default.
• W4387356970 creator A5080398125 @default.
• W4387356970 creator A5090924104 @default.
• W4387356970 creator A5092251979 @default.
• W4387356970 creator A5093006209 @default.
• W4387356970 date "2023-10-04" @default.
• W4387356970 modified "2023-10-12" @default.
• W4387356970 title "Indication for a Pneumocystis Prophylaxis Therapy in Patients with Vascular Anomalies Treated with PIK3/AKT/mTOR Pathway Inhibitors: Experts’ Opinion and Systematic Review from the Literature" @default.
• W4387356970 cites W1502172390 @default.
• W4387356970 cites W1706136667 @default.
• W4387356970 cites W1969250830 @default.
• W4387356970 cites W1969832654 @default.
• W4387356970 cites W2000239178 @default.
• W4387356970 cites W2000566468 @default.
• W4387356970 cites W2003835506 @default.
• W4387356970 cites W2007135130 @default.
• W4387356970 cites W2078112947 @default.
• W4387356970 cites W2116649409 @default.
• W4387356970 cites W2142387449 @default.
• W4387356970 cites W2319623531 @default.
• W4387356970 cites W2392938395 @default.
• W4387356970 cites W2465495680 @default.
• W4387356970 cites W2585315210 @default.
• W4387356970 cites W2796364945 @default.
• W4387356970 cites W2797779447 @default.
• W4387356970 cites W2807345376 @default.
• W4387356970 cites W2808211602 @default.
• W4387356970 cites W2966571020 @default.
• W4387356970 cites W2981038324 @default.
• W4387356970 cites W3093797023 @default.
• W4387356970 cites W3126380139 @default.
• W4387356970 cites W3132250091 @default.
• W4387356970 cites W3155326873 @default.
• W4387356970 cites W3190371698 @default.
• W4387356970 cites W3193998431 @default.
• W4387356970 cites W3195176880 @default.
• W4387356970 cites W3200511178 @default.
• W4387356970 cites W4220781690 @default.
• W4387356970 cites W4237637945 @default.
• W4387356970 cites W4283824459 @default.
• W4387356970 doi "https://doi.org/10.1159/000533675" @default.
• W4387356970 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37793356" @default.
• W4387356970 hasPublicationYear "2023" @default.
• W4387356970 type Work @default.
• W4387356970 citedByCount "0" @default.
• W4387356970 crossrefType "journal-article" @default.
• W4387356970 hasAuthorship W4387356970A5001564881 @default.
• W4387356970 hasAuthorship W4387356970A5042930843 @default.
• W4387356970 hasAuthorship W4387356970A5051498016 @default.
• W4387356970 hasAuthorship W4387356970A5056285508 @default.
• W4387356970 hasAuthorship W4387356970A5064459488 @default.
• W4387356970 hasAuthorship W4387356970A5065871425 @default.
• W4387356970 hasAuthorship W4387356970A5080398125 @default.
• W4387356970 hasAuthorship W4387356970A5090924104 @default.
• W4387356970 hasAuthorship W4387356970A5092251979 @default.
• W4387356970 hasAuthorship W4387356970A5093006209 @default.
• W4387356970 hasConcept C126322002 @default.
• W4387356970 hasConcept C17744445 @default.
• W4387356970 hasConcept C183713625 @default.
• W4387356970 hasConcept C185592680 @default.
• W4387356970 hasConcept C189708586 @default.
• W4387356970 hasConcept C190283241 @default.
• W4387356970 hasConcept C199539241 @default.
• W4387356970 hasConcept C2777559004 @default.
• W4387356970 hasConcept C2777914695 @default.
• W4387356970 hasConcept C2777921159 @default.
• W4387356970 hasConcept C2779473830 @default.
• W4387356970 hasConcept C2779699572 @default.
• W4387356970 hasConcept C2908647359 @default.
• W4387356970 hasConcept C55493867 @default.
• W4387356970 hasConcept C71924100 @default.
• W4387356970 hasConcept C86554907 @default.
• W4387356970 hasConcept C99454951 @default.
• W4387356970 hasConceptScore W4387356970C126322002 @default.
• W4387356970 hasConceptScore W4387356970C17744445 @default.
• W4387356970 hasConceptScore W4387356970C183713625 @default.
• W4387356970 hasConceptScore W4387356970C185592680 @default.
• W4387356970 hasConceptScore W4387356970C189708586 @default.
• W4387356970 hasConceptScore W4387356970C190283241 @default.
• W4387356970 hasConceptScore W4387356970C199539241 @default.
• W4387356970 hasConceptScore W4387356970C2777559004 @default.
• W4387356970 hasConceptScore W4387356970C2777914695 @default.
• W4387356970 hasConceptScore W4387356970C2777921159 @default.
• W4387356970 hasConceptScore W4387356970C2779473830 @default.
• W4387356970 hasConceptScore W4387356970C2779699572 @default.
• W4387356970 hasConceptScore W4387356970C2908647359 @default.
• W4387356970 hasConceptScore W4387356970C55493867 @default.
• W4387356970 hasConceptScore W4387356970C71924100 @default.
• W4387356970 hasConceptScore W4387356970C86554907 @default.
• W4387356970 hasConceptScore W4387356970C99454951 @default.
• W4387356970 hasLocation W43873569701 @default.

• next